 Bone Remodeling
"Bone Remodeling" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium homeostasis. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
| Descriptor ID |
D016723
|
| MeSH Number(s) |
G11.427.590.195 G16.100.856.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bone Remodeling".
Below are MeSH descriptors whose meaning is more specific than "Bone Remodeling".
This graph shows the total number of publications written about "Bone Remodeling" by people in UAMS Profiles by year, and whether "Bone Remodeling" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 2 | 3 | | 2019 | 2 | 1 | 3 | | 2018 | 2 | 0 | 2 | | 2017 | 1 | 2 | 3 | | 2016 | 6 | 2 | 8 | | 2015 | 2 | 1 | 3 | | 2014 | 1 | 3 | 4 | | 2013 | 3 | 3 | 6 | | 2012 | 6 | 4 | 10 | | 2011 | 2 | 0 | 2 | | 2010 | 5 | 2 | 7 | | 2009 | 2 | 1 | 3 | | 2008 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2005 | 0 | 2 | 2 | | 2004 | 1 | 0 | 1 | | 2003 | 1 | 2 | 3 | | 2002 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1995 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Bone Remodeling" by people in Profiles over the past ten years.
-
Cawley KM, Bustamante-Gomez NC, Guha AG, MacLeod RS, Xiong J, Gubrij I, Liu Y, Mulkey R, Palmieri M, Thostenson JD, Goellner JJ, O'Brien CA. Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption. Cell Rep. 2020 09 08; 32(10):108052.
-
Miyagawa K, Ohata Y, Delgado-Calle J, Teramachi J, Zhou H, Dempster DD, Subler MA, Windle JJ, Chirgwin JM, Roodman GD, Kurihara N. Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo. JCI Insight. 2020 03 26; 5(6).
-
Ponte F, Kim HN, Iyer S, Han L, Almeida M, Manolagas SC. Cxcl12 Deletion in Mesenchymal Cells Increases Bone Turnover and Attenuates the Loss of Cortical Bone Caused by Estrogen Deficiency in Mice. J Bone Miner Res. 2020 08; 35(8):1441-1451.
-
Kegelman CD, Coulombe JC, Jordan KM, Horan DJ, Qin L, Robling AG, Ferguson VL, Bellido TM, Boerckel JD. YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling. J Bone Miner Res. 2020 01; 35(1):196-210.
-
Huseman CJ, Sigler DH, Welsh TH, Suva LJ, Vogelsang MM, Dominguez BJ, Huggins S, Paulk C. Skeletal response to whole body vibration and dietary calcium and phosphorus in growing pigs. J Anim Sci. 2019 Jul 30; 97(8):3369-3378.
-
Saito H, Gasser A, Bolamperti S, Maeda M, Matthies L, Jähn K, Long CL, Schlüter H, Kwiatkowski M, Saini V, Pajevic PD, Bellido T, van Wijnen AJ, Mohammad KS, Guise TA, Taipaleenmäki H, Hesse E. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nat Commun. 2019 03 22; 10(1):1354.
-
Pacheco-Costa R, Davis HM, Atkinson EG, Dilley JE, Byiringiro I, Aref MW, Allen MR, Bellido T, Plotkin LI. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 09; 114:22-31.
-
Kegelman CD, Mason DE, Dawahare JH, Horan DJ, Vigil GD, Howard SS, Robling AG, Bellido TM, Boerckel JD. Skeletal cell YAP and TAZ combinatorially promote bone development. FASEB J. 2018 05; 32(5):2706-2721.
-
Piemontese M, Almeida M, Robling AG, Kim HN, Xiong J, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA, Jilka RL. Old age causes de novo intracortical bone remodeling and porosity in mice. JCI Insight. 2017 09 07; 2(17).
-
Pellegrini GG, Cregor M, McAndrews K, Morales CC, McCabe LD, McCabe GP, Peacock M, Burr D, Weaver C, Bellido T. Nrf2 regulates mass accrual and the antioxidant endogenous response in bone differently depending on the sex and age. PLoS One. 2017; 12(2):e0171161.
-
Maria S, Swanson MH, Enderby LT, D'Amico F, Enderby B, Samsonraj RM, Dudakovic A, van Wijnen AJ, Witt-Enderby PA. Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures. Aging (Albany NY). 2017 Jan 26; 9(1):256-285.
-
Kalaitzoglou E, Popescu I, Bunn RC, Fowlkes JL, Thrailkill KM. Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep. 2016 12; 14(6):310-319.
-
Hoscheit M, Conner G, Roemer J, Vuckovska A, Abbasnia P, Vana P, Shankar R, Kennedy R, Callaci J. Burn Injury Has Skeletal Site-Specific Effects on Bone Integrity and Markers of Bone Remodeling. J Burn Care Res. 2016 Nov/Dec; 37(6):367-378.
-
Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini GG, Kuhlenschmidt K, Olivos N, Robling A, Peacock M, Plotkin LI, Bellido T. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor. J Bone Miner Res. 2017 Mar; 32(3):522-535.
-
Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol. 2016 Oct; 12(10):593-605.
-
Alund AW, Mercer KE, Suva LJ, Pulliam CF, Chen JR, Badger TM, Van Remmen H, Ronis MJ. Reactive Oxygen Species Differentially Regulate Bone Turnover in an Age-Specific Manner in Catalase Transgenic Female Mice. J Pharmacol Exp Ther. 2016 07; 358(1):50-60.
-
Piemontese M, Onal M, Xiong J, Han L, Thostenson JD, Almeida M, O'Brien CA. Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage. Sci Rep. 2016 Apr 11; 6:24262.
-
Zangari M, Suva LJ. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone. 2016 May; 86:131-8.
-
Jilka RL, O'Brien CA. The Role of Osteocytes in Age-Related Bone Loss. Curr Osteoporos Rep. 2016 Feb; 14(1):16-25.
-
Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, Bonewald L, Manolagas SC, O'Brien CA. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One. 2015; 10(9):e0138189.
-
Deng L, Wang Y, Peng Y, Wu Y, Ding Y, Jiang Y, Shen Z, Fu Q. Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts. Bone. 2015 Oct; 79:37-42.
-
Bhutani M, Landgren O, Usmani SZ. Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book. 2015; e493-503.
-
Hill Gallant KM, Gallant MA, Brown DM, Sato AY, Williams JN, Burr DB. Raloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats. PLoS One. 2014; 9(9):e108262.
-
Issa K, Stroh AD, Mont MA, Bonutti PM. Effect of bone type on clinical and radiographic outcomes of a proximally-coated cementless stem in primary total hip arthroplasties. J Orthop Res. 2014 Sep; 32(9):1214-20.
-
Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G, de Bono J, Eccles SA, Davies FE, Robinson SP. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst. 2014 Apr; 106(4):dju033.
-
Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res. 2014 Jan; 29(1):103-17.
-
Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014 Jan; 94(1):25-34.
-
Manolagas SC, Cummings SR. Skeletal aging: from bench to bed side. J Gerontol A Biol Sci Med Sci. 2013 Oct; 68(10):1195-6.
-
Rhee Y, Lee EY, Lezcano V, Ronda AC, Condon KW, Allen MR, Plotkin LI, Bellido T. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem. 2013 Oct 11; 288(41):29809-20.
-
Cassat JE, Hammer ND, Campbell JP, Benson MA, Perrien DS, Mrak LN, Smeltzer MS, Torres VJ, Skaar EP. A secreted bacterial protease tailors the Staphylococcus aureus virulence repertoire to modulate bone remodeling during osteomyelitis. Cell Host Microbe. 2013 Jun 12; 13(6):759-72.
-
Spatz JM, Ellman R, Cloutier AM, Louis L, van Vliet M, Suva LJ, Dwyer D, Stolina M, Ke HZ, Bouxsein ML. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013 Apr; 28(4):865-74.
-
Bartell SM, Han L, Kim HN, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Chambliss KL, Shaul PW, Roberson PK, Weinstein RS, Jilka RL, Almeida M, Manolagas SC. Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol Endocrinol. 2013 Apr; 27(4):649-56.
-
Jilka RL, Noble B, Weinstein RS. Osteocyte apoptosis. Bone. 2013 Jun; 54(2):264-71.
-
Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone. 2013 Jun; 54(2):250-7.
-
McKelvey KD, Fowler TW, Akel NS, Kelsay JA, Gaddy D, Wenger GR, Suva LJ. Low bone turnover and low bone density in a cohort of adults with Down syndrome. Osteoporos Int. 2013 Apr; 24(4):1333-8.
-
Fowler TW, McKelvey KD, Akel NS, Vander Schilden J, Bacon AW, Bracey JW, Sowder T, Skinner RA, Swain FL, Hogue WR, Leblanc DB, Gaddy D, Wenger GR, Suva LJ. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment. PLoS One. 2012; 7(8):e42967.
-
Mercer KE, Wynne RA, Lazarenko OP, Lumpkin CK, Hogue WR, Suva LJ, Chen JR, Mason AZ, Badger TM, Ronis MJ. Vitamin D supplementation protects against bone loss associated with chronic alcohol administration in female mice. J Pharmacol Exp Ther. 2012 Nov; 343(2):401-12.
-
Li X, Ling W, Khan S, Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 2012 Aug; 27(8):1635-48.
-
Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. Receptor activator of nuclear factor ?B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012 Aug 24; 287(35):29851-60.
-
Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012 Mar; 27(3):499-505.
-
Calvi LM, Bromberg O, Rhee Y, Weber JM, Smith JN, Basil MJ, Frisch BJ, Bellido T. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012 Mar 15; 119(11):2489-99.
-
Turek J, Ebetino FH, Lundy MW, Sun S, Kashemirov BA, McKenna CE, Gallant MA, Plotkin LI, Bellido T, Duan X, Triffitt JT, Russell RG, Burr DB, Allen MR. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int. 2012 Mar; 90(3):202-10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|